Author Archives: admin


The personal and professional collide in a scientist’s story of early human development – Science Magazine

Magdalena Zernicka-Goetz and Roger HighfieldBasic Books2020304 pp.Purchase this item now

With one phone call, Magdalena Zernicka-Goetzs life as a scientist collided with her personal life in the most dramatic way. As Zernicka-Goetz stood at her desk at the University of Cambridge, a genetic counselor explained that some cells derived from the placenta supporting her fetus carried a serious chromosomal anomaly. But her knowledge of how embryos develop suggested that the fetus might be able to exclude the cells with the genetic abnormality or that it may not contain the damaged DNA at all. Further testing confirmed that the fetus was genetically normal, and her son was born in perfect health. At the time, however, she writes, I couldnt possibly be sure.

In The Dance of Life, Zernicka-Goetz and science writer Roger Highfield weave Zernicka-Goetzs personal memoir together with an accessible introduction to contemporary mouse and human embryonic research and with a discussion of the clinical, ethical, and societal implications of this research and related areas. This is a lofty goal for a relatively slim volume, and it succeeds better in some parts than in others.

Developmental biologists have studied the progression of the fertilized mammalian egg through its early cleavage divisions to the formation of the 100-cell blastocyst for many years. Such studies have suggested that there is a gradual segregation of cell fate influenced by cell polarity, cell position (inside or outside), and mechanical signals and that the embryo is able to regulate for loss, gain, or rearrangement of cells right up to the blastocyst stage. However, none of these studies really addressed the question of whether there might be asymmetries in the egg or early embryo that could bias later cell fate.

Zernicka-Goetz, who has long been fascinated with patterning in the early embryo, took on this challenge when she began her own research lab at the University of Cambridge. She describes her work on defining early asymmetries in the mouse embryo and their role in informing later development in careful detail, recounting how she used tools such as cell marking, live imaging, and gene manipulation to determine that early blastomeres show a bias toward different regions and cell types of the blastocyst. However, other researchersusing different techniquesfound less evidence for early differences, leading to some vigorous debates, as described in the book.

This controversy compelled researchers who had set aside work on the early embryo to reenter the fray, bringing new tools and ideas. And, although it is still not clear what initiates asymmetries after fertilization, it is increasingly clear that by the four-cell stage, there are differences in chromatin modification and transcription factor activity among the cells that, while not permanently specifying cell fate, may bias their future lineage contributions.

The book does not shy away from discussing the moral and ethical implications inherent in such research, tackling prenatal testing, the ongoing quest to create synthetic embryos, and the question of whether human embryos should be used in research. Although an early embryo is not a person, I believe that it deserves protection, and I fully appreciate that balancing that protection with scientific research is not easy, writes Zernicka-Goetz of the latter issue. Her attitude has been to tread carefully, weighing potential concerns against potential value to humanity. I believe in taking a measured approach to enable research that is fully consistent with our values.

The authors do their best to describe experiments on the early embryo and stem cellbased embryo models in simple terms, but the book would have been greatly enhanced by the inclusion of some illustrations. The early embryo is truly beautiful, especially when the complexity of gene expression patterns is revealed by fluorescent imaging. Also, some of the science may be hard for the uninitiated to follow. In the fifth chapter, for example, the embryonic cleavage divisions from one cell to four cells are described using a two-tone soccer ball analogy. This takes two full paragraphs to explain a concept that could have been easily conveyed with a simple diagram.

The most engaging parts of The Dance of Life are the personal stories about the trials and tribulations Zernicka-Goetz has faced during her life in science. Scientific disagreements occur, papers get rejected, grants are not funded, and balancing family and work is never easy. Those of us who, like Zernicka-Goetz, are developmental biologists are in the fortunate position of being in a field where many leading scientists are women (no all-male panels for us!), but female scientists still struggle to overcome the persistent biases and societal and institutional barriers that block their progress. At the end of the day howeveras Zernicka-Goetz and Highfield so ably showthe thrill of scientific discovery is what keeps us coming back to the bench.

The reviewer is president and scientific director of the Gairdner Foundation, Toronto, ON M5G 1L7, Canada, and a senior scientist at the Hospital for Sick Children, University of Toronto, Toronto, ON M5G 0A4, Canada.

More:
The personal and professional collide in a scientist's story of early human development - Science Magazine

Global Cancer Stem Cell Therapy Market 2020: What Are The Key Trends In Market? – Chronicles 99

The latest version of the 2020 market study on Cancer Stem Cell Therapy Market comprising 97 with market data Tables, Charts, Graphs, and Figures which are easy to understand with showcased in-depth analysis.

The global Cancer Stem Cell Therapy market size is estimated at xxx million USD with a CAGR xx% from 2015-2019 and is expected to reach xxx Million USD in 2020 with a CAGR xx% from 2020 to 2025. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Cancer Stem Cell Therapy by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

Check out sample report at: https://www.amplemarketreports.com/sample-request/global-cancer-stem-cell-therapy-market-1351346.html

As per the research and study, the market has settled its presence worldwide. Cancer Stem Cell Therapy Market Research study offers a comprehensive evaluation of the Market and comprises a future trend, current growth factors, focused opinions, details, and industry certified market data.

Glancing to 2020, the global market expected to be a significant year for Cancer Stem Cell Therapy Market in terms of growth and revenue.

Almost all companies who are listed or profiled are being to upgrade their applications for end-user experience and setting up their permanent base in 2020. This report focused and concentrate on these companies including AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems.

Furthermore, the research contributes an in-depth overview of regional level break-up categorized as likely leading growth rate territory, countries with the highest market share in past and current scenario. Some of the geographical break-up incorporated in the study are AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems.

With the Cancer Stem Cell Therapy market forecast to expand CAGR% in 2020 and with X-X-X-X supposed to be a big beneficiary, it is better positioned than Z-Z-Z-Z for 2020.

According to the AMR market study, Recent trends in consumer preferences market segments such as type, application will be more challenging. Cancer Stem Cell Therapy market segment sales will traverse the $$ mark in 2020.

Unlike classified segments successful in the industry such as by Type (Autologous Stem Cell Transplants, Allogeneic Stem Cell Transplants, Syngeneic Stem Cell Transplants, Others) and by End-Users/Application (Hospital, Clinic, Medical Research Institution, Others).

The 2020 version of the Cancer Stem Cell Therapy market study is a further split down / narrowed to highlight the latest emerging twist of the industry.

Enquire more before buy at: https://www.amplemarketreports.com/enquiry-before-buy/global-cancer-stem-cell-therapy-market-1351346.html

Due to a change in consumer preferences with a review on the latest sales and revenue report submissions, Major vendors in the Global market are trying to get the attention of end-users or consumers by Offerings and additional services.

With using the latest technology and analysis on demand-side, Key players are getting in consumer behavior and their changing preferences.

Again, big investment firms or giants are willing to put more capital to get a key players performance in the market for new applications or products.

Discount, Know more this research report at: https://www.amplemarketreports.com/discount-request/global-cancer-stem-cell-therapy-market-1351346.html

Research Objectives and Purpose

Read More about this report at: https://www.amplemarketreports.com/report/global-cancer-stem-cell-therapy-market-1351346.html

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Western / Eastern Europe or Southeast Asia.

With the given market data, Research on Global Markets offers customizations according to specific needs. Write to AMR at sales@amplemarketreports.com, or connect via +1-530-868-6979

About Author

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Our end goal is to provide quality market research and consulting services to customers and add maximum value to businesses worldwide. We desire to delivery reports that have the perfect concoction of useful data. Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Address:

William James

Media & Marketing Manager

Address: 3680 Wilshire Blvd, Ste P04 1387 Los Angeles, CA 90010

Call: +1 (530) 868 6979

Email: sales@amplemarketreports.com

https://www.amplemarketreports.com

Read more:
Global Cancer Stem Cell Therapy Market 2020: What Are The Key Trends In Market? - Chronicles 99

Longevity and Anti-senescence Therapy Market Analysis, Segmentation, Key Players, Opportunities and Forecast 2020 2026 – Galus Australis

This Longevity and Anti-senescence Therapy Market research report is focused at providing its reader with all the necessary details that can help them make necessary business decisions. It provides wholesome information that is necessary to understand the market inside-out.

ReportsnReports has recently added a new research report to its expanding repository. The research report, titled Longevity and Anti-senescence Therapy Market, mainly includes a detailed segmentation of this sector, which is expected to generate massive returns by the end of the forecast period, thus showing an appreciable rate of growth over the coming years on an annual basis. The research study also looks specifically at the need for Longevity and Anti-senescence Therapy Market.

Report Scope:

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which include stem cell-based therapies, etc.

Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.

The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.

Download A Sample Report athttps://www.reportsnreports.com/contacts/requestsample.aspx?name=2255402

Report Includes:

71 data tables and 40 additional tables An overview of the global longevity and anti-senescence therapy market Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023 Country specific data and analysis for the United States, Canada, Japan, China, India, U.K., France, Germany, Spain, Australia, Middle East and Africa Detailed description of various anti-senescence therapies, such as senolytic drug therapy, gene therapy, immunotherapy and other stem cell therapies, and their influence in slowing down aging or reverse aging process Coverage of various therapeutic drugs, devices and technologies and information on compounds used for the development of anti-ageing therapeutics A look at the clinical trials and expected launch of anti-senescence products Detailed profiles of the market leading companies and potential entrants in the global longevity and anti-senescence therapy market, including AgeX Therapeutics, CohBar Inc., PowerVision Inc., T.A. Sciences and Unity Biotechnology

Summary:

Global longevity and anti-senescence therapy market deals in the adoption of different therapies and treatment options used to extend human longevity and lifespan. Human longevity is typically used to describe the length of an individuals lifetime and is sometimes used as a synonym for life expectancy in the demography. Anti-senescence is the process by which cells stop dividing irreversibly and enter a stage of permanent growth arrest, eliminating cell death. Anti-senescence therapy is used in the treatment of senescence induced through unrepaired DNA damage or other cellular stresses.

Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and an increasing demand for cell-based assays in research and development.

An increasing geriatric population across the globe and rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and the anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).

According to the National Institutes of Health (NIH), the total geriatric population across the globe in 2016 was over REDACTED. By 2022, the global geriatric population (65 years and above) is anticipated to reach over REDACTED. An increasing geriatric population across the globe will generate huge growth prospectus to the market.

Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics, etc. are working extensively in this field for the extension of human longevity by focusing on study of genomics, microbiome, bioinformatics and stem cell therapies, etc. These factors are poised to drive market growth over the forecast period.

Please Share Your Specific Interest To Serve You Better | Download PDF Brochure athttps://www.reportsnreports.com/contacts/requestsample.aspx?name=2255402

Global longevity and anti-senescence market is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach REDACTED, registering REDACTED in growth from REDACTED in 2018.

The report provides analysis based on each market segment including therapies and application. The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy and Others. Senolytic drug therapy held the largest market revenue share of REDACTED in 2017. By 2023, total revenue from senolytic drug therapy is expected to reach REDACTED. Gene therapy segment is estimated to rise at the highest CAGR of REDACTED till 2023. The fastest growth of the gene therapy segment is due to the Large investments in genomics. For Instance; The National Human Genome Research Institute (U.S.) had a budget grant of REDACTED for REDACTED research projects in 2015, thus increasing funding to REDACTED for approximately REDACTED projects in 2016.

Recent Industry Trend:

The report contains the profiles of various prominent players in the Global Longevity and Anti-senescence Therapy Market. Different strategies implemented by these vendors have been analyzed and studied in order to gain a competitive edge, create unique product portfolios and increase their market share. The study also sheds light on major global industry vendors. Such essential vendors consist of both new and well-known players. In addition, the business report contains important data relating to the launch of new products on the market, specific licenses, domestic scenarios and the strategies of the organization implemented on the market.

Access Full Report athttps://www.reportsnreports.com/purchase.aspx?name=2255402

Scope of the Report:

Through following the Longevity and Anti-senescence Therapy Market through depth, the readers should find this study very helpful. The aspects and details are depicted by charts, bar graphs, pie diagrams, and other visual representations in the longevity and Anti-senescence Therapy Market study. This intensifies the representation of the pictures and also helps to improve the facts of the Longevity and Anti-senescence Therapy Market industry. At a substantial CAGR, the Longevity and Anti-senescence Therapy Market is likely to grow. Longevity and Anti-senescence Therapy Market reports main objective is to guide the user to understand the market in terms of its definition, classification, industry potential, the latest trends, and the challenges facing the Longevity and Anti-senescence Therapy Market.

And More

About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.We provide 24/7 online and offline support to our customers.

E-mail: sales@reportsandreports.com

Phone: +1 888 391 5441

See the original post:
Longevity and Anti-senescence Therapy Market Analysis, Segmentation, Key Players, Opportunities and Forecast 2020 2026 - Galus Australis

Mice with diabetes "functionally cured" using new stem cell therapy – New Atlas

Diabetes is characterized by trouble producing or managing insulin, and one emerging treatment involves converting stem cells into beta cells that secrete the hormone. Now, scientists have developed a more efficient method of doing just that, and found that implanting these cells in diabetic mice functionally cured them of the disease.

The study builds on past research by the same team, led by Jeffrey Millman at Washington University. The researchers have previously shown that infusing mice with these cells works to treat diabetes, but the new work has had even more impressive results.

These mice had very severe diabetes with blood sugar readings of more than 500 milligrams per deciliter of blood levels that could be fatal for a person and when we gave the mice the insulin-secreting cells, within two weeks their blood glucose levels had returned to normal and stayed that way for many months, says Millman.

Insulin is normally produced by beta cells in the pancreas, but in people with diabetes these cells dont produce enough of the hormone. The condition is usually managed by directly injecting insulin into the bloodstream when its needed. But in recent years, researchers have found ways to convert human stem cells into beta cells, which can pick up the slack and produce more insulin.

In the new study, the team improved that technique. Usually when converting stem cells into a specific type of cell, a few random mistakes are made, so some other types of cells end up in the mix. These are harmless, but arent exactly pulling their weight for the job at hand.

The more off-target cells you get, the less therapeutically relevant cells you have, says Millman. You need about a billion beta cells to cure a person of diabetes. But if a quarter of the cells you make are actually liver cells or other pancreas cells, instead of needing a billion cells, youll need 1.25 billion cells. It makes curing the disease 25 percent more difficult.

So, the new method was focused on reducing those unwanted extras. By targeting the cytoskeleton, the underlying structure that gives cells their shape, the team was able to not only produce a higher percentage of beta cells, but they also functioned better.

Its a completely different approach, fundamentally different in the way we go about it, said Millman. Previously, we would identify various proteins and factors and sprinkle them on the cells to see what would happen. As we have better understood the signals, weve been able to make that process less random.

When these new-and-improved beta cells were infused into diabetic mice, their blood sugar levels were stabilized, rendering the diabetes functionally cured for up to nine months.

Of course, at this stage its just an animal trial, so the results may not translate to humans any time soon, if ever. But the researchers plan to continue the work by testing the cells in larger animals over longer periods, with hopes of one day getting the treatment ready for human clinical trials.

The research was published in the journal Nature Biotechnology.

Source: Washington University

See original here:
Mice with diabetes "functionally cured" using new stem cell therapy - New Atlas

Consistent Outcomes Using Ryoncil as First-Line Treatment or Salvage Therapy in 309 Children With Steroid-Refractory Acute GVHD – BioSpace

NEW YORK, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that aggregated results from 309 children treated with Ryoncil (remestemcel-L) were presented atthe American Society for Transplantation Cellular Therapy and the Center for International Blood & Bone Marrow Transplant Research (TCT) meeting in Orlando, Florida on February 22. The data showed that treatment with RYONCIL across three separate trials resulted inconsistent treatment responses and survival outcomesinchildren with steroid-refractory acute graft versus host disease (SR-aGVHD).

Key findings and conclusions were:

Mesoblast Chief Medical Officer Dr Fred Grossman said: These aggregated data from three studies demonstrate consistent efficacy and safety of RYONCIL in children suffering from steroid refractory acute graft versus host disease. If approved, RYONCIL has the potential to be an effective and safe therapy to improve survival outcomes in the most vulnerable population of children with severe forms of this disease who can have mortality rates as high as 90 percent.

In January, Mesoblast filed a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for RYONCIL for the treatment of children with steroid-refractory aGVHD. The Company has requested Priority Review of the BLA by the FDA under the product candidates existing Fast Track designation. If approved, RYONCIL is expected to be launched in the US in 2020.

About Acute GVHDAcute GVHD occurs in approximately 50% of patients who receive an allogeneic bone marrow transplant (BMT). Over 30,000 patients worldwide undergo an allogeneic BMT annually, primarily during treatment for blood cancers, and these numbers are increasing.1 In patients with the most severe form of acute GVHD (Grade C/D or III/IV) mortality is as high as 90% despite optimal institutional standard of care.2,3. There are currently no FDA-approved treatments in the US for children under 12 with SR-aGVHD.

About Ryoncil Mesoblasts lead product candidate, RYONCIL, is an investigational therapy comprising culture- expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor. It is administered to patients in a series of intravenous infusions. RYONCIL is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in SR- aGVHD by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.

References1. Niederwieser D, Baldomero H, Szer J. (2016) Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey.2. Westin, J., Saliba, RM., Lima, M. (2011) Steroid-refractory acute GVHD: predictors and outcomes. Advances in Hematology.3. Axt L, Naumann A, Toennies J (2019) Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation.

About MesoblastMesoblast Limited (Nasdaq: MESO; ASX: MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platforms to establish a broad portfolio of commercial products and late-stage product candidates. Mesoblasts proprietary manufacturing process yields industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has filed a Biologics License Application to the United States Food and Drug Administration (FDA) to seek approval of its product candidate Ryoncil (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GvHD). Remestemcel-L is also being developed for other rare diseases. Mesoblast is completing Phase 3 trials for its rexlemestrocel product candidates for advanced heart failure and chronic low back pain. If approved, RYONCIL is expected to be launched in the United States in 2020 for pediatric steroid-refractory acute GVHD. Two products have been commercialized in Japan and Europe by Mesoblasts licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see http://www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Mesoblasts Forward-Looking StatementsThis announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about the timing, progress and results of Mesoblasts preclinical and clinical studies; Mesoblasts ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblasts product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblasts actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

Visit link:
Consistent Outcomes Using Ryoncil as First-Line Treatment or Salvage Therapy in 309 Children With Steroid-Refractory Acute GVHD - BioSpace

Stem Cell Alopecia Treatment Market Size, Current Trends, Business Opportunities, Market Challenges and Analysis by 2026 – News Parents

The report carefully examines the Stem Cell Alopecia Treatment Market, with a focus on most of the major players and their business strategies, geographical scope, market segments, product landscape and price and cost structure. Each section of the research study is specially prepared to investigate key aspects of the Stem Cell Alopecia Treatment market. The area of market activity, for example, drivers, restrictions, trends and opportunities in the global market for Stem Cell Alopecia Treatment is explored in detail. Through qualitative and quantitative analysis, we support you in a comprehensive and comprehensive analysis of the Stem Cell Alopecia Treatment market. We also focus on the five forces analysis of SWOT, PESTLE and Porter in the Stem Cell Alopecia Treatment market.

Request a Sample Copy of this Report @ https://www.verifiedmarketresearch.com/download-sample/?rid=15102&utm_source=NPN&utm_medium=007

The main Companies operating in the Stem Cell Alopecia Treatment Market are listed in the report.

Stem Cell Alopecia Treatment Market: Competitive Landscape

The players who lead the Stem Cell Alopecia Treatment market are analyzed taking into account their market share, the latest developments, new manufacturers, associations, acquisitions and markets. We also provide a comprehensive analysis of your product portfolio to explore the product and the applications that you focus on while operating in the Stem Cell Alopecia Treatment market. In addition, the report offers two different market forecasts: one is the production side and the other on the use side of the Stem Cell Alopecia Treatment market. It also provides practical advice for newcomers, as well as for established players in the world of smart camera market.

Stem Cell Alopecia Treatment Market: Segment Analysis

This chapter focuses on the different segments in the Stem Cell Alopecia Treatment market. The report segments the market by type, application, product, service and end user. This division enables a detailed view of the motif. It helps to understand the changes in production and the general needs of consumers that are likely to affect these segments.

Stem Cell Alopecia Treatment Market: Regional Analysis

The chapter on regional analysis highlights the political scenario in emerging and industrialized countries that is expected to affect the dynamics of supply and demand. Regional analysis also helps identify the changing needs of the population that have a critical impact on the general market for Stem Cell Alopecia Treatment . This part of the research report also took into account labor costs, raw materials and production costs by region.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=15102&utm_source=NPN&utm_medium=007

Table of Content

1 Introduction of Stem Cell Alopecia Treatment Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Alopecia Treatment Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Alopecia Treatment Market , By Deployment Model

5.1 Overview

6 Stem Cell Alopecia Treatment Market , By Solution

6.1 Overview

7 Stem Cell Alopecia Treatment Market , By Vertical

7.1 Overview

8 Stem Cell Alopecia Treatment Market , By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Alopecia Treatment Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Report Customization @ https://www.verifiedmarketresearch.com/product/stem-cell-alopecia-treatment-market/?utm_source=NPN&utm_medium=007

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

TAGS: Stem Cell Alopecia Treatment Market Size, Stem Cell Alopecia Treatment Market Growth, Stem Cell Alopecia Treatment Market Forecast, Stem Cell Alopecia Treatment Market Analysis, Stem Cell Alopecia Treatment Market Trends, Stem Cell Alopecia Treatment Market

Visit link:
Stem Cell Alopecia Treatment Market Size, Current Trends, Business Opportunities, Market Challenges and Analysis by 2026 - News Parents

When Treating Women With Ovarian Cancer, Gynecologic Oncologist Emphasizes Openness And Dedication Throughout Journey – Forbes

By Jodi Helmer

When Heidi E. Godoy, D.O., gynecologic oncologist, sees new ovarian cancer patients for the first time, she starts preparing them for the likelihood their cancer will return.

Dr. Heidi E. Godoy, gynecologic oncologist

For those unfamiliar with the disease, Godoys early focus on recurrence may seem premature. But she believes that being upfront about the realities of ovarian cancer is as important as discussing the initial treatment, which is typically surgery followed by platinum-based chemotherapy.

Ovarian cancer is difficult to diagnose, increasing the odds that it wont be discovered until it reaches an advanced stage. And in 85% of late-stage ovarian cancer cases, the disease recurs, according to research published in the International Journal of Surgical Oncology.1

One of the first conversations I have with patients outlines the relapse that often happens with ovarian cancer, said Godoy, who works in private practice in New York State and is affiliated with several hospitals there. I dont want it to be a surprise if the cancer returns.

Godoy also makes it a point to reassure women living with ovarian cancer that she will be with them throughout their cancer journey. Gynecologic oncologists, she explained, generally provide complete care, from diagnosis to surgery, for cancers affecting the ovaries, uterus, cervix, vulva and vagina. Holistic care is one of the reasons she pursued the subspecialty.

When I was going through medical school, I wanted a subspecialty that provided a lot of continuity of care, Godoy recalled. In gynecologic oncology, you develop such personalized, deep relationships with your patients.

Expert, Empathetic Care

For women living with ovarian cancer, receiving treatment from a gynecologic oncologist can simplify care and provide a sense of familiarity with their treatment teams. Research published in Frontiers In Oncology2 in 2015 shows that the highly-trained medical professionals also provide positive clinical outcomes.

Gynecologic oncologists perform complex procedures such as surgical debulkinga tumor-removal procedure that often affects other organsto remove the entire tumor and improve the prognosis. They are among the only specialists that perform surgical debulking, Godoy said. While surgery and chemotherapy are well-known components of treatment plans, maintenance therapies have become meaningful options for doctors in recent years.

Ovarian cancer patients who have a response to platinum-based chemotherapy in the recurrent setting are candidates for PARP inhibitors, one of those being niraparib or ZEJULA, Godoy explained.

Those candidatespatients who recur after a first-line treatment and receive a second line of platinum-based chemotherapyreally need to have that conversation about starting maintenance therapy, she continued.

The current approach of watch-and-wait, where we take them off their chemotherapy or their cytotoxic therapy and just watch and wait to see if the cancer returns, is no longer the only option, Godoy said. Maintenance therapy has changed the paradigm of watching and waiting to see if the cancer returns.

ZEJULA, made by the pharmaceutical company GSK, is a prescription medicine used for the maintenance treatment of adults with ovarian cancer, fallopian tube cancer or primary peritoneal cancer, when the cancer comes back. ZEJULA is used after the cancer has responded (complete or partial response) to treatment with platinum-based chemotherapy. It can also be used for treatment of adults with advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer who have been treated with three or more prior types of chemotherapy and who have tumors with a certain BRCA gene mutation, or a positive laboratory test, and whose cancer was in response to treatment with platinum-based chemotherapy, and who have progressed more than six months after the last treatment. For treatment in the late-line setting, your healthcare provider will perform a test to make sure that ZEJULA is right for you.

ZEJULA has serious risks such as bone marrow problems called MDS or a type of blood cancer called AML. Low blood cell counts are common. Tell your doctor about any weakness, tiredness, infections, fever, shortness of breath, blood in urine or stool, bruising, bleeding or weight loss. High blood pressure is common and can become serious. Nausea and constipation are also common.

Benefiting From More Recent Treatment Options

The idea of maintenance therapy to treat ovarian cancer is not new, Godoy said. Until recently, however, only intravenous forms of maintenance therapy were available, which required women to receive the treatment in clinics.

More recent treatment options for ovarian cancer include oral medications, like ZEJULA, which give women the ability to take it at home. ZEJULA is taken once a day.

Women living with ovarian cancer are often surprised to learn that maintenance therapies exist, she added. For the newly diagnosed, Godoy offered important advice.

If you have ovarian cancer, ask your OB/GYN to make a referral to a gynecologic oncologist and have a meeting with them to discuss your care, she said. Learn more about current treatments, including maintenance therapy, and be your own best advocate.

Jodi Helmer writes about health, science and innovation.

Important Safety Information

ZEJULA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of blood cancer called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during treatment with ZEJULA. MDS or AML may lead to death.

Symptoms of low blood cell counts (low red blood cells, low white blood cells, and low platelets) are common during treatment with ZEJULA. They can be a sign of serious bone marrow problems, including MDS or AML. These symptoms may include the following:

Your doctor will do blood tests to check your blood cell counts before treatment with ZEJULA. You will be tested weekly for the first month of treatment with ZEJULA, monthly for the next 11 months of treatment, and from time to time afterward.

High blood pressure is common during treatment with ZEJULA, and it can become serious. Your doctor will check your blood pressure and heart rate at least weekly for the first two months, then monthly for the first year, and as needed thereafter during your treatment with ZEJULA.

Before starting to take ZEJULA, tell your doctor about all of your medical conditions, including if you:

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of ZEJULA include the following:

o Heart not beating regularly

o Nausea

o Constipation

o Vomiting

o Pain in the stomach area

o Mouth sores

o Diarrhea

o Indigestion or heartburn

o Dry mouth

o Tiredness

o Loss of appetite

o Urinary tract infection

o Shortness of breath

o Cough

o Rash

o Changes in liver function or other blood tests

o Pain in your joints, muscles, and back

o Headache

o Dizziness

o Change in the way food tastes

o Trouble sleeping

o Anxiety

o Sore throat

o Changes in the amount or color of your urine

If you have certain side effects, then your doctor may change your dose of ZEJULA, temporarily stop, or permanently stop treatment with ZEJULA.

These are not all the possible side effects of ZEJULA. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

For full prescribing information visit http://www.ZEJULA.com/prescribing-information.

NP-NIR-US-0004

NRPJRNA200001

Continued here:
When Treating Women With Ovarian Cancer, Gynecologic Oncologist Emphasizes Openness And Dedication Throughout Journey - Forbes

Immune-Based Therapies Emerge in Mantle Cell Lymphoma – Curetoday.com

Patients with the aggressive blood cancer can turn to immunotherapies like CAR-T cell therapy when disease recurs or becomes resistant.

Immunotherapies, such as chimeric antigen receptor (CAR)-T cell therapy, are advancing the therapy landscape for these patients.

CAR-T cell therapy has shown significant benefits in this patient population, Dr. Charalambos (Babis) Andreadis, said in an interview with OncLive, a sister publication of CURE. In patients with relapsed/refractory MCL, both lisocabtagene maraleucel (JCAR017) and axicabtagene ciloleucel (Yescarta) have shown 70% to 90% response rates and 50% to 60% (complete response) rates. That is going to be the future of this field.

Mantle cell lymphoma is an aggressive, rare form of non-Hodgkin lymphoma (NHL) that accounts for about 6% of all NHL cases in the United States. The disease results from a malignant transformation of a B lymphocyte in the outer edge of a lymph node follicle, or the mantle zone, according to The Leukemia & Lymphoma Society.

Mantle cell lymphoma is a disease that responds well to initial therapy, so we try to throw (everything we have) at it (early), Andreadis, an associate professor of clinical medicine in the Department of Medicine at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, said. When a patient relapses, ibrutinib (Imbruvica) or a BTK-like agent is the drug of choice.

Types of BTK inhibitors include Imbruvica, Calquence (acalabrutinib) and Brukinsa (zanubrutinib). The responses seen with these drugs have led to approvals from the Food and Drug Administration for patients who have received at least one prior line of therapy. But often patients will relapse following BTK inhibitor therapy. The median duration of response is about 1 to 1.5 years, Andreadis explained.

As another approach to treatment, researchers are examining the effects of CAR-T cell therapy. During the 2019 American Society of Hematology annual meeting, results from the ZUMA-2 clinical trial showed promise in the investigational CAR-T cell therapy KTE-X19. The phase 3 trial included patients with relapsed and/or refractory mantle cell lymphoma who had received multiple prior lines of therapy. Patients received a single infusion of KTE-X19, and the researchers saw a 93% objective response rate and a 67% complete response rate.

Right now, we are asking, In what patient population can we use CAR-T cell therapy in? Andreadis said. Can we give it to patients with central nervous system disease? What about other lymphomas like follicular lymphoma? Can we give it in the clinic? We are getting the data that may increase the applicability of CAR-T cell therapy in those areas.

Although there is much hope in the use of CAR-T cell therapy, not all patients respond, or treatment may stop working. Thats where experts are exploring antibody-drug conjugates and bispecific T-cell engagers (BiTEs). We saw response rates of 50% to 70% in patients treated with bispecific antibodies, some whom failed CAR T prior, he said.

He added, Going forward, we need to get CAR T more affordable and accessible. We also need to work to simplifying the procedure, perhaps by using allogeneic CAR T cells.

Originally posted here:
Immune-Based Therapies Emerge in Mantle Cell Lymphoma - Curetoday.com

Texas A&M Researcher Named To National List Of Inspiring Black Scientists – Texas A&M University

Texas A&M researcher Dr. Yava Jones Hall was named to a list of 100 inspiring black scientists in the U.S.

Texas A&M College of Veterinary Medicine & Biomedical Sciences

Dr. Yava Jones-Hall, an associate professor in theDepartment of Veterinary Pathobiology (VTPB)at the Texas A&M College of Veterinary Medicine & Biomedical Sciences (CVM), is leading in the field of veterinary medicine as the only veterinarian selected for CrossTalks list of100 inspiring black scientists in America.

CrossTalk is the official blog of Cell Press, a leading publisher of more than 50 scientific journals across the life, physical, earth and health sciences.

We are very happy to see one of our high-caliber faculty members being recognized for their outstanding work, said Carol A. Fierke, Texas A&M University provost and executive vice president.

Jones-Hall is joined on the list by scientists from African, Afro-Caribbean, Afro-Latinx and African-American backgrounds ranging from assistant professors to department heads at universities across the country.

It was surprising and amazing to be selected, especially being a veterinarian, Jones-Hall said. It was nice to see veterinary medicine represented.

The list of inspiring black scientists was created to encourage current and future generations of scientists and emphasize the importance of diversity in the field. CrossTalk clarified that while there are many more than 100 black scientists in the U.S. deserving of recognition, the list was created to provide an example of the impact black scientists can have on America.

Diversity drives excellence in everything that we do as a team, including biomedical education and research, saidDr. Ramesh Vemulapalli, VTPB department head. We are very proud to have Dr. Jones-Hall on our faculty. She is a great role model to minority students aspiring to pursue a career in veterinary medicine.

I definitely see diversity in veterinary medicine as an important concept, Jones-Hall said. The reality is, the world is not homogenous. We need our students to be exposed to working with different types of people to have cultural sensitivity and understand that not everybody is like you. Also, once you have diversity within any program, you get diverse ideas.

While earning her Doctor of Veterinary Medicine (DVM) degree at the Tuskegee University College of Veterinary Medicine, Jones-Hall was introduced to the field of patholog they, study of the causes and effects of disease. Once she saw how seamlessly pathology combines with collaborative research, she was hooked.

As a veterinary pathologist, Im trained to understand disease in any organ in a multitude of species, Jones-Hall said. Whatever field of research an investigators in, I help them figure out how best a pathologist can tease out the data for them to see whats happening and how best to frame the research.

Considering herself a veterinary detective, Jones-Hall helps researchers look at clues in cells and body tissues to find the best way for the research to progress. Working on a variety of research topics, and never knowing what will come through the door next, are what make the field of pathology so appealing to her.

Jones-Hall joined the CVM from the Purdue University College of Veterinary Medicine last August and, as the sirector of CVMs Histology Laboratory, began the project of creating a digital pathology program to increase the efficiency and accuracy of one of a pathologists typical jobs analyzing slides of cells to count those of the same kind.

Traditionally, pathologists would look at the slide under the microscope and give a subjective assessment of disease, Jones-Hall said. Digital pathology augments traditional pathology by allowing the pathologist to use computer-generated algorithms to assess disease. This gives objective, quantifiable, and repeatable results. Whereas it would take me weeks to look at hundreds of slides, I scan the slides to make a digital image and direct a computer program to find the cells of interest or disease state. Hundreds of slides can now be analyzed in hours instead of weeks.

Outside of the lab, Jones-Hall donates much of her spare time to volunteering for community outreach efforts and taking any opportunity she can to promote STEM careers, and specifically veterinary medicine, to disadvantaged youth.

She is also a member of Texas A&Ms STRIDE (Strategies and Tactics for Recruiting to Improve Diversity and Excellence) Committee, leading workshops for faculty members involved in faculty recruitment.

Diversity is important, in general, and its important to me, so Im willing to do more in order to improve the climate and increase everyones awareness she said.

Jones-Hall hopes that her recognition from CrossTalk can inspire others to spend their careers thinking not only of themselves, but also those who may not have had the same advantages.

The CVM is extremely proud of Dr. Jones-Hall for her accomplishments as an individual and as the only veterinarian to appear on the list of 100 inspiring black scientists, saidDr. Eleanor M. Green, the Carl B. King Dean of Veterinary Medicine. The work she does within and outside of the university will undoubtedly make a huge impact, both for the college and within the community, as she demonstrates the possibilities for budding scientists from all backgrounds.

Original post:
Texas A&M Researcher Named To National List Of Inspiring Black Scientists - Texas A&M University

Cumberland County family turns to non-FDA approved stem cell treatment to help two-year-old son with cerebral palsy – FOX43.com

Lance was diagnosed with cerebral palsy a year ago. His family hopes non-FDA approved stem cell treatment for the disease can help him walk and talk.

CAMP HILL, Pa. A family in Cumberland County has turned to stem cells to treat their two-year-old son diagnosed with cerebral palsy. The only problem: stem cell treatment for the disease hasn't been approved by the FDA.

The day he was born, when he wheeled him down the hall and he was only a pound, and I started to cry and said, will he live? And he said, of course Hes only small," said Danielle Maxwell, Lance's mom.

The words, "he's only small," are what Lance's mom and father Rob have lived by since the day he was born. The preemie, born three months early, has been through several surgeries and complications along the way. But, Lance has always been a fighter.

Lance fought so hard just to survive the beginning of life, and come home with us," said Danielle. "And he is just so happy and loving and amazing.

About a year ago, Lance was diagnosed with cerebral palsy. Doctors told his family, he will never walk, talk or take care of himself.

We just dont believe that," said Danielle. "We dont.

Lance receives a lot of different therapies but, his parents did not want to just stop there.

We both overwhelmingly feel, he never gave up, he never gave up on us, he never gave up on himself," said Rob. "So, we owe it to him to give him the opportunity. Its really that simple, he deserves the opportunity."

Danielle began researching stem cell therapies, even speaking to doctors in countries overseas where treatment with stem cells is more readily accessible than in the U.S. The FDA has approved stem cell treatments for some conditions but not cerebral palsy. However, trials to determine the effectiveness of stem cell treatment for the disease are underway.

What weve seen is a small but real appearing improvement in motor function," said Doctor Charles Cox with University of Texas Health in Houston, began a trial in 2013 on the safety and effectiveness of banked cord blood or bone marrow stem cells in children with cerebral palsy, and is now just wrapping up the results from the trial.

The overall results of this study depend if youre a glass half full or half empty kind of person," said Dr. Cox. "It is not a compelling miraculous result. Its not, Oh my God, this child was treated and look at this profound benefit.'"

Because stem cell treatment for cerebral palsy is still in trial phases, it's not approved treatment by the FDA. However, the Maxwells did find a doctor in Harrisburg willing to transfer stem cells from a full-term baby's umbilical cord to Lance. But, since it isn't FDA approved, we were not allowed to be there to show Lance receiving the stem cells. The Maxwells are hopeful following this procedure Lance may someday walk and more importantly be able to communicate with them.

He wants to be involved," said Rob. "You can tell hes trying to communicate he just cant get over that hump. We believe stem cells could be that bridge to help him move a little faster.

Danielle says, it will take about six months to see if the stem cells will have any definitive benefits for Lance. But, already says she's seeing progress. She says Lance is not able to stand on his own.

More:
Cumberland County family turns to non-FDA approved stem cell treatment to help two-year-old son with cerebral palsy - FOX43.com